Helen Torley Sells 10,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Rating) CEO Helen Torley sold 10,000 shares of the stock in a transaction on Tuesday, March 7th. The stock was sold at an average price of $45.47, for a total value of $454,700.00. Following the completion of the transaction, the chief executive officer now directly owns 623,666 shares of the company’s stock, valued at approximately $28,358,093.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Helen Torley also recently made the following trade(s):

• On Thursday, March 9th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $42.73, for a total value of $427,300.00.
• On Thursday, February 16th, Helen Torley sold 11,061 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $49.26, for a total value of $544,864.86.
• On Wednesday, February 8th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $51.36, for a total value of $513,600.00.
• On Thursday, January 19th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $52.41, for a total value of $524,100.00.
• On Thursday, December 15th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $57.37, for a total value of $573,700.00.

Halozyme Therapeutics Stock Performance

Shares of Halozyme Therapeutics stock opened at $41.63 on Friday. Halozyme Therapeutics, Inc. has a 12 month low of $34.00 and a 12 month high of $59.46. The company has a quick ratio of 4.88, a current ratio of 5.65 and a debt-to-equity ratio of 8.79. The stock has a market cap of $5.64 billion, a PE ratio of 28.71, a price-to-earnings-growth ratio of 0.55 and a beta of 1.26. The business has a fifty day simple moving average of $50.30 and a 200-day simple moving average of $48.78.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. SVB Leerink decreased their target price on Halozyme Therapeutics from $62.00 to $61.00 and set an “outperform” rating for the company in a research note on Wednesday, January 11th. Wells Fargo & Company assumed coverage on Halozyme Therapeutics in a research note on Monday, November 28th. They set an “overweight” rating and a $65.00 target price for the company. JMP Securities reaffirmed a “market outperform” rating and set a $66.00 target price (up previously from $62.00) on shares of Halozyme Therapeutics in a research note on Wednesday, February 22nd. Morgan Stanley decreased their target price on Halozyme Therapeutics from $65.00 to $64.00 and set an “overweight” rating for the company in a research note on Monday, March 6th. Finally, JPMorgan Chase & Co. dropped their price target on Halozyme Therapeutics from $54.00 to $52.00 and set an “overweight” rating on the stock in a research note on Thursday, February 23rd. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $62.29.

Institutional Investors Weigh In On Halozyme Therapeutics

Institutional investors have recently bought and sold shares of the business. Victory Capital Management Inc. increased its holdings in shares of Halozyme Therapeutics by 18.4% in the 4th quarter. Victory Capital Management Inc. now owns 1,415,356 shares of the biopharmaceutical company’s stock valued at $80,534,000 after purchasing an additional 219,670 shares during the period. Sheets Smith Wealth Management purchased a new stake in shares of Halozyme Therapeutics in the fourth quarter worth approximately $260,000. Rockefeller Capital Management L.P. lifted its position in shares of Halozyme Therapeutics by 228.4% in the fourth quarter. Rockefeller Capital Management L.P. now owns 32,883 shares of the biopharmaceutical company’s stock worth $1,871,000 after purchasing an additional 22,869 shares in the last quarter. Natixis lifted its position in shares of Halozyme Therapeutics by 346.4% in the fourth quarter. Natixis now owns 167,847 shares of the biopharmaceutical company’s stock worth $9,550,000 after purchasing an additional 130,247 shares in the last quarter. Finally, Teachers Retirement System of The State of Kentucky lifted its position in shares of Halozyme Therapeutics by 10.0% in the fourth quarter. Teachers Retirement System of The State of Kentucky now owns 28,690 shares of the biopharmaceutical company’s stock worth $1,633,000 after purchasing an additional 2,600 shares in the last quarter. 96.32% of the stock is currently owned by institutional investors and hedge funds.

About Halozyme Therapeutics

(Get Rating)

Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.